VISTA H-Score Is Significantly Associated with a 5-Year DFS Rate in Oral Squamous Cell Carcinoma

Article Biology

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Pottayil G. Sasikumar et al.

Summary: CA-170 is a small molecule inhibitor that activates T cells and exhibits anti-tumor efficacy in mouse models, advancing to human clinical trials for its potential as an anti-cancer drug.

COMMUNICATIONS BIOLOGY (2021)

Add to Collection

Article Oncology

High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer

Liju Zong et al.

Summary: The study revealed that high VISTA expression in CRC patients correlates with early tumor staging, MMR deficiency, and favorable prognosis. This provides important insights for future trials of VISTA-modulating immunotherapy targeting CRC patients.

JOURNAL OF IMMUNOTHERAPY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma-Potential Biomarkers for Targeted Therapy Concepts

Nora Wuerdemann et al.

Summary: This study investigated the expression of LAG-3, TIM-3, and VISTA in OPSCC, confirming a significant correlation between CD8+ T cells and the expression of these immune checkpoints. The findings suggest that immune checkpoint therapy targeting LAG-3, TIM-3, and/or VISTA could be a promising treatment strategy, especially in HPV-related OPSCC. Future clinical trials considering LAG-3, TIM-3, and VISTA expression are necessary to further explore the efficacy of checkpoint blockade therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Prognostic significance and therapeutic potential of the immune checkpoint VISTA in pancreatic cancer

Zelin Hou et al.

Summary: VISTA expression in tumor cells is associated with favorable prognosis in pancreatic cancer patients. The study showed that VISTA level is positively correlated with different immune cell subclusters in PDAC, and anti-VISTA therapy can effectively reduce metastatic nodules in mouse models with liver metastases of PDAC.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer

Xi Cao et al.

Summary: The study evaluated the expression of V-domain Ig suppressor of T-cell activation (VISTA) in triple-negative breast cancer patients and found that VISTA-positive immune cells were associated with better prognosis. It suggested that VISTA could be a potential therapeutic target for TNBC.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy

Yu Yuan et al.

Summary: Immune checkpoint blockade targeting PD-1/PD-L1 has shown promising therapeutic efficacy in various tumors, but resistance can hinder its effectiveness. This review examines the role of PD-L1 in therapy resistance, particularly through the PD-1/PD-L1 pathway, and highlights potential combination therapies to overcome this resistance.

CANCERS (2021)

Add to Collection

Article Multidisciplinary Sciences

The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis

Amina Ghouzlani et al.

Summary: The study found that VISTA gene expression is significantly upregulated in glioma tissues, specifically in patient tissues compared to PBMC of healthy donors. VISTA has higher expression levels in higher grade glioma patients and shows a positive correlation with PD-1 expression. Additionally, VISTA is associated with poor prognosis in glioma patients, suggesting it may be a potential therapeutic target in advanced gliomas.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

ZNF-281 as the Potential Diagnostic Marker of Oral Squamous Cell Carcinoma

Anna Starzynska et al.

Summary: Zinc-finger-281 (ZNF-281) has been reported to influence cancer progression and metastasis, with its up-regulation associated with worsened prognosis in many cancers. This pilot study examined ZNF-281's expression in oral squamous cell carcinoma (OSCC), finding that its levels were significantly decreased compared to healthy tissue, suggesting its potential as an OSCC-specific marker. Further investigation of ZNF-281's role in OSCC is warranted.

CANCERS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

High PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of the Mouth but Not in Other Oral Compartments

Lukasz Jan Adamski et al.

Summary: The study analyzed the immunohistochemical expression of PD-L1 and IL-33 in 95 chemonaive OSCCs. High PD-L1 expression in TILs was associated with better overall survival, and the expression varied based on tumor location and cell type.

BIOMEDICINES (2021)

Add to Collection

Article Oncology